This suggests that gene therapy (i.e., select delivery of GRβ to the TM) could become a therapeutic option to treat those patients (e.g., with persistent and vision-threatening uveitis) who develop GC-OHT and secondary glaucoma. Here, GZMB is linked to glaucoma.